Trial · NCT03566823
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Clinical Remission Based on 2-item Patient-reported Outcome (PRO) at Week 16 | Placebo | 3 | Participants | ||
| Number of Participants With Clinical Remission Based on 2-item Patient-reported Outcome (PRO) at Week 16 | Ontamalimab 25 mg | 5 | Participants | ||
| Number of Participants With Clinical Remission Based on 2-item Patient-reported Outcome (PRO) at Week 16 | Ontamalimab 75 mg | 5 | Participants | ||
| Number of Participants With Endoscopic Response at Week 16 | Placebo | 2 | Participants | ||
| Number of Participants With Endoscopic Response at Week 16 | Ontamalimab 25 mg | 10 | Participants | ||
| Number of Participants With Endoscopic Response at Week 16 | Ontamalimab 75 mg | 10 | Participants | ||
| Number of Participants With Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 16 | Placebo | 4 | Participants | ||
| Number of Participants With Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 16 | Ontamalimab 25 mg | 8 | Participants | ||
| Number of Participants With Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 16 | Ontamalimab 75 mg | 6 | Participants | ||
| Number of Participants With Enhanced Endoscopic Response at Week 16 | Placebo | 2 | Participants | ||
| Number of Participants With Enhanced Endoscopic Response at Week 16 | Ontamalimab 25 mg | 5 | Participants | ||
| Number of Participants With Enhanced Endoscopic Response at Week 16 | Ontamalimab 75 mg | 3 | Participants | ||
| Number of Participants With Clinical Remission Based on 2-item PRO With 4-point Scale for Abdominal Pain at Week 16 | Placebo | 3 | Participants | ||
| Number of Participants With Clinical Remission Based on 2-item PRO With 4-point Scale for Abdominal Pain at Week 16 | Ontamalimab 25 mg | 6 | Participants | ||
| Number of Participants With Clinical Remission Based on 2-item PRO With 4-point Scale for Abdominal Pain at Week 16 | Ontamalimab 75 mg | 6 | Participants | ||
| Number of Participants With Clinical Response Based on 2-item PRO With 2 Criteria at Week 16 | Placebo | 5 | Participants | ||
| Number of Participants With Clinical Response Based on 2-item PRO With 2 Criteria at Week 16 | Ontamalimab 25 mg | 11 | Participants | ||
| Number of Participants With Clinical Response Based on 2-item PRO With 2 Criteria at Week 16 | Ontamalimab 75 mg | 8 | Participants | ||
| Number of Participants With Clinical Remission Based on 2-Item PRO With Endoscopic Response at Week 16 | Placebo | 1 | Participants | ||
| Number of Participants With Clinical Remission Based on 2-Item PRO With Endoscopic Response at Week 16 | Ontamalimab 25 mg | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03566823/results